Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olli Kallioniemi

Showing results (161-170 of 185) with videos related to

Pageof 19
Sort By:
British Journal of Cancer|December 8, 2022
Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinomaAstrid Murumägi, Daniela Ungureanu, Suleiman Khan, et al.
Scientific Reports|February 7, 2018
ITGB1-dependent upregulation of Caveolin-1 switches TGFβ signalling from tumour-suppressive to oncogenic in prostate cancerTeijo Pellinen, Sami Blom, Sara Sánchez, et al.
The Journal of Pathology|February 15, 2018
Spatial aspects of oncogenic signalling determine the response to combination therapy in slice explants from Kras-driven lung tumoursKatja Närhi, Ashwini S Nagaraj, Elina Parri, et al.
NPJ Precision Oncology|March 12, 2026
Midostaurin response in AML is shaped by a progenitor-like cell state selectively targeted by SMAC mimeticsNona Struyf, Henrik Gezelius, Anders Lundmark, et al.
Oncotarget|February 11, 2017
Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitorsPaavo O Pietarinen, Christopher A Eide, Pilar Ayuda-Durán, et al.
Blood|June 17, 2017
JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AMLRiikka Karjalainen, Tea Pemovska, Mihaela Popa, et al.
Genes, Chromosomes & Cancer|August 21, 2010
Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumorsDavid J McBride, Arto K Orpana, Christos Sotiriou, et al.
Cancer Research|March 19, 2011
Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progressionMika Hilvo, Carsten Denkert, Laura Lehtinen, et al.
Blood|April 19, 2013
Discovery of somatic STAT5b mutations in large granular lymphocytic leukemiaHanna L M Rajala, Samuli Eldfors, Heikki Kuusanmäki, et al.
Nature Biotechnology|June 2, 2014
A community effort to assess and improve drug sensitivity prediction algorithmsJames C Costello, Laura M Heiser, Elisabeth Georgii, et al.
Pageof 19

Showing results (161-170 of 185) with videos related to

Sort By:
Pageof 19
British Journal of Cancer|December 8, 2022
Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinomaAstrid Murumägi, Daniela Ungureanu, Suleiman Khan, et al.
Scientific Reports|February 7, 2018
ITGB1-dependent upregulation of Caveolin-1 switches TGFβ signalling from tumour-suppressive to oncogenic in prostate cancerTeijo Pellinen, Sami Blom, Sara Sánchez, et al.
The Journal of Pathology|February 15, 2018
Spatial aspects of oncogenic signalling determine the response to combination therapy in slice explants from Kras-driven lung tumoursKatja Närhi, Ashwini S Nagaraj, Elina Parri, et al.
NPJ Precision Oncology|March 12, 2026
Midostaurin response in AML is shaped by a progenitor-like cell state selectively targeted by SMAC mimeticsNona Struyf, Henrik Gezelius, Anders Lundmark, et al.
Oncotarget|February 11, 2017
Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitorsPaavo O Pietarinen, Christopher A Eide, Pilar Ayuda-Durán, et al.
Blood|June 17, 2017
JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AMLRiikka Karjalainen, Tea Pemovska, Mihaela Popa, et al.
Genes, Chromosomes & Cancer|August 21, 2010
Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumorsDavid J McBride, Arto K Orpana, Christos Sotiriou, et al.
Cancer Research|March 19, 2011
Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progressionMika Hilvo, Carsten Denkert, Laura Lehtinen, et al.
Blood|April 19, 2013
Discovery of somatic STAT5b mutations in large granular lymphocytic leukemiaHanna L M Rajala, Samuli Eldfors, Heikki Kuusanmäki, et al.
Nature Biotechnology|June 2, 2014
A community effort to assess and improve drug sensitivity prediction algorithmsJames C Costello, Laura M Heiser, Elisabeth Georgii, et al.
Pageof 19